(NASDAQ: UNCY) Unicycive Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Unicycive Therapeutics's revenue in 2026 is $0.On average, 11 Wall Street analysts forecast UNCY's revenue for 2026 to be $10,432,156, with the lowest UNCY revenue forecast at $0, and the highest UNCY revenue forecast at $49,805,200. On average, 10 Wall Street analysts forecast UNCY's revenue for 2027 to be $3,909,763,873, with the lowest UNCY revenue forecast at $932,649,715, and the highest UNCY revenue forecast at $8,984,156,040.
In 2028, UNCY is forecast to generate $14,905,348,021 in revenue, with the lowest revenue forecast at $5,615,341,259 and the highest revenue forecast at $30,000,111,789.